R
Robert Yarchoan
Researcher at National Institutes of Health
Publications - 336
Citations - 21558
Robert Yarchoan is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Virus & Primary effusion lymphoma. The author has an hindex of 78, co-authored 315 publications receiving 20045 citations. Previous affiliations of Robert Yarchoan include Keio University & St. Vincent's Health System.
Papers
More filters
Journal Article
Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro.
Laurence A. Rubin,C. C. Kurman,M E Fritz,William E. Biddison,B Boutin,Robert Yarchoan,David L. Nelson +6 more
TL;DR: The release of soluble IL 2R appears to be a characteristic marker of T lymphocyte activation and might serve an immunoregulatory function during both normal and abnormal cell growth and differentiation.
Journal ArticleDOI
Molecular targets for AIDS therapy
TL;DR: In the future, non-nucleoside-type drugs will likely become more important in the experimental therapy of AIDS, and antiretroviral therapy will exert major effects against the morbidity and mortality caused by HIV.
Journal ArticleDOI
Cancer Burden in the HIV-Infected Population in the United States
Meredith S. Shiels,Ruth M. Pfeiffer,Mitchell H. Gail,H. Irene Hall,Jianmin Li,Anil K. Chaturvedi,Kishor Bhatia,Thomas S. Uldrick,Robert Yarchoan,James J. Goedert,Eric A. Engels +10 more
TL;DR: Over a 15-year period (1991-2005), increases in non-AIDS-defining cancers were mainly driven by growth and aging of the AIDS population, which requires targeted cancer prevention and treatment strategies.
Journal ArticleDOI
CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection.
Henry Masur,Frederick P. Ognibene,Robert Yarchoan,James H. Shelhamer,Barbara F. Baird,William D. Travis,Anthony F. Suffredini,Lawrence Deyton,J A Kovacs,Judith Falloon +9 more
TL;DR: Pneumocystis pneumonia, cytomegalovirus pneumonia, and pulmonary infection caused by C. neoformans or M. avium-intracellulare are unlikely to occur in HIV-infected patients who have had a CD4 count above 0.200 to 0.250 X 10(9) cells/L or aCD4 percent above 20% to 25% in the 60 days before pulmonary evaluation.
Journal ArticleDOI
Phase i studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (azt)
Robert Yarchoan,Rose V. Thomas,Jean-Pierre Allain,Nanette McAtee,Richard Dubinsky,Hiroaki Mitsuya,Thomas J. Lawley,Bijan Safai,Charles E. Myers,Carlo Federico Perno,Raymond W. Klecker,Robert J. Wills,Margaret A. Fischl,M. Carol Mcneely,James M. Pluda,Michael Leuther,Jerry M. Collins,Samuel Broder +17 more
TL;DR: It is suggested that ddC has activity against HIV in vivo and has a different toxicity profile from that of zidovudine (AZT).